Literature DB >> 19625257

Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart.

Zamaneh Kassiri1, Virginie Defamie, Mehrdad Hariri, Gavin Y Oudit, Shalini Anthwal, Fayez Dawood, Peter Liu, Rama Khokha.   

Abstract

The pleiotropic cytokines, transforming growth factor beta1 (TGFbeta1), and tumor necrosis factor (TNF) play critical roles in tissue homeostasis in response to injury and are implicated in multiple human diseases and cancer. We reported that the loss of Timp3 (tissue inhibitor of metalloproteinase 3) leads to abnormal TNF signaling and cardiovascular function. Here we show that parallel deregulation of TGFbeta1 and TNF signaling in Timp3(-/-) mice amplifies their cross-talk at the onset of cardiac response to mechanical stress (pressure overload), resulting in fibrosis and early heart failure. Microarray analysis showed a distinct gene expression profile in Timp3(-/-) hearts, highlighting activation of TGFbeta1 signaling as a potential mechanism underlying fibrosis. Neonatal cardiomyocyte-cardiofibroblast co-cultures were established to measure fibrogenic response to agonists known to be induced following mechanical stress in vivo. A stronger response occurred in neonatal Timp3(-/-) co-cultures, as determined by increased Smad signaling and collagen expression, due to increased TNF processing and precocious proteolytic maturation of TGFbeta1 to its active form. The relationship between TGFbeta1 and TNF was dissected using genetic and pharmacological manipulations. Timp3(-/-)/Tnf(-/-) mice had lower TGFbeta1 than Timp3(-/-), and anti-TGFbeta1 antibody (1D11) negated the abnormal TNF response, indicating their reciprocal stimulatory effects, with each manipulation abolishing fibrosis and improving heart function. Thus, TIMP3 is a common innate regulator of TGFbeta1 and TNF in tissue response to injury. The matrix-bound TIMP3 balances the anti-inflammatory and proinflammatory processes toward constructive tissue remodeling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625257      PMCID: PMC2785619          DOI: 10.1074/jbc.M109.028449

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA.

Authors:  M Bitzer; G von Gersdorff; D Liang; A Dominguez-Rosales; A A Beg; M Rojkind; E P Böttinger
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

3.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

4.  Expression analysis of the entire MMP and TIMP gene families during mouse tissue development.

Authors:  Robert K Nuttall; Clara L Sampieri; Caroline J Pennington; Sean E Gill; Gilbert A Schultz; Dylan R Edwards
Journal:  FEBS Lett       Date:  2004-04-09       Impact factor: 4.124

Review 5.  Diastolic heart failure.

Authors:  L Mandinov; F R Eberli; C Seiler; O M Hess
Journal:  Cardiovasc Res       Date:  2000-03       Impact factor: 10.787

6.  Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase.

Authors:  Philipp Stawowy; Christian Margeta; Heike Kallisch; Nabil G Seidah; Michel Chrétien; Eckart Fleck; Kristof Graf
Journal:  Cardiovasc Res       Date:  2004-07-01       Impact factor: 10.787

7.  Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.

Authors:  Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 8.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.

Authors:  Karen Hogg; Karl Swedberg; John McMurray
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

9.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.

Authors:  Michael R Zile; Catalin F Baicu; William H Gaasch
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

Review 10.  Role of angiotensin II AT1 receptor activation in cardiovascular diseases.

Authors:  Sandrine Billet; Fréderick Aguilar; Camille Baudry; Eric Clauser
Journal:  Kidney Int       Date:  2008-07-23       Impact factor: 10.612

View more
  42 in total

1.  Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3.

Authors:  Quteba Ebrahem; Jian Hua Qi; Masahiko Sugimoto; Mariya Ali; Jonathan E Sears; Alecia Cutler; Rama Khokha; Amit Vasanji; Bela Anand-Apte
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-03       Impact factor: 4.799

Review 2.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

3.  Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy.

Authors:  Deqiang Li; Ying Liu; Mitsunori Maruyama; Wuqiang Zhu; Hanying Chen; Wenjun Zhang; Sean Reuter; Shien-Fong Lin; Laura S Haneline; Loren J Field; Peng-Sheng Chen; Weinian Shou
Journal:  Hum Mol Genet       Date:  2011-08-31       Impact factor: 6.150

Review 4.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

5.  Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction.

Authors:  Vijay Kandalam; Ratnadeep Basu; Thomas Abraham; Xiuhua Wang; Ahmed Awad; Wei Wang; Gary D Lopaschuk; Nobuyo Maeda; Gavin Y Oudit; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-30       Impact factor: 4.733

Review 6.  Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

Authors:  Hassan K Awada; Mintai P Hwang; Yadong Wang
Journal:  Biomaterials       Date:  2015-12-29       Impact factor: 12.479

7.  Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction.

Authors:  Shaina R Eckhouse; Brendan P Purcell; Jeremy R McGarvey; David Lobb; Christina B Logdon; Heather Doviak; Jason W O'Neill; James A Shuman; Craig P Novack; Kia N Zellars; Sara Pettaway; Roy A Black; Aarif Khakoo; Taeweon Lee; Rupak Mukherjee; Joseph H Gorman; Robert C Gorman; Jason A Burdick; Francis G Spinale
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

8.  Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling.

Authors:  David C Lobb; Heather Doviak; Gregory L Brower; Eva Romito; Jason W O'Neill; Stephen Smith; James A Shuman; Parker D Freels; Kia N Zellars; Lisa A Freeburg; Aarif Y Khakoo; TaeWeon Lee; Francis G Spinale
Journal:  J Pharmacol Exp Ther       Date:  2020-09-21       Impact factor: 4.030

9.  TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.

Authors:  Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Mengcheng Shen; Vaibhav B Patel; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

Review 10.  Membrane-associated matrix proteolysis and heart failure.

Authors:  Francis G Spinale; Joseph S Janicki; Michael R Zile
Journal:  Circ Res       Date:  2013-01-04       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.